Indias Race to Manufacture Affordable Obesity Drugs Amid Ozempics Market Entry Following the March 20, 2026 patent expiry of semaglutide, India is witnessing a rapid influx of generic GLP-1 receptor agonists
But the majority of covered workers in America still sit inside plans that exclude these medications for weight management entirely, even as the same plans often cover the identical molecules when prescribed for diabetes
Table 2 gives an overview on the cardiovascular safety data of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, and sitagliptin
Compounds including gallic acid, ferulic acid, and caffeic acid have shown the potential to scavenge reactive oxygen species (ROS), protect against neuronal death, and reduce neuroinflammation by downregulating pro-inflammatory cytokines like TNF- and IL-6
Some people notice appetite changes within weeks, while weight loss and blood sugar improvements may continue for several months